{Reference Type}: Journal Article
{Title}: EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.
{Author}: Giustini NP;Pritchard CC;Kamat NV;Menon MP;
{Journal}: JCO Precis Oncol
{Volume}: 8
{Issue}: 0
{Year}: 2024 Jul
{Factor}: 5.479
{DOI}: 10.1200/PO.23.00215
{Abstract}: Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.